Netherlands: Rapid Response 2016

The Rapid Response program was created to catalyze and jumpstart the development of safe and effective treatments for these diseases. The program provides short-term grants as seed funding for novel, high-risk, high-reward translational research projects. Proposed projects may relate to any disease; however, the basis for selection will be on the potential impact of the project on neurodegenerative diseases of aging.

 


UPR activity as early biomarker for tauopathies

Grantees: Dr. Wiep Scheper

Project description The majority of dementias, including Alzheimer’s disease, are characterized by accumulation of aggregates (“clumps”) of the protein tau. These age-related neurodegenerative diseases present an increasing socio-economic burden....

More


Determination of the cholinergic deficit in early Parkinson’s disease, using the novel PET imaging marker [18F] Fluoroethoxybenzovesamicol (FEOBV)

Grantees: Dr. Teus van Laar

Project description Parkinson’s disease (PD) is a progressive neurological disorder and is best known for its motor impairments, including rigidity, slowness of movement and tremor. However, not only the...

More


Plasma ceramides and CERT proteins as prognostic biomarkers for AD

Grantees: Dr. Pilar Martinez

Project Description Accumulating research suggests that pathophysiological changes associated with Alzheimer’s Disease (AD) begin at least 10 to 25 years before dementia onset.  There are currently no means of...

More


Developing New MRI Connectome Biomarkers of Disease Outcome for Amyotrophic Lateral Sclerosis (ALS)

Grantees: Dr. Martijn van den Heuvel , Ruben Schmidt , Dr. Leonard van den Berg

Project description Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease with a median survival of 3 to 5 years after symptom onset. A considerable proportion (30%) of...

More